Lataa...
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody–Associated Encephalopathy
IMPORTANCE: This observational study describes the efficacy and safety of rituximab in 5 patients with voltage-gated potassium channel (VGKC)–complex/leucine-rich, glioma-inactivated 1 (LGI1) antibody–associated encephalopathy. Rituximab is a monoclonal antibody that targets CD20 and is used to trea...
Tallennettuna:
| Julkaisussa: | JAMA Neurol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4477824/ https://ncbi.nlm.nih.gov/pubmed/24842754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2014.463 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|